UroGen Pharma (URGN) Gross Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly Gross Margin came in at 91.88% in Q1 2026, up 338.0% YoY from 20.98% in Q1 2025, and up 0.62% on a QoQ basis from 91.31% in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) Gross Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Gross Margin data on file, last reported at 91.88% in Q1 2026.
- Quarterly Gross Margin rose 338.0% year-over-year to 91.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.85% (up 17.0% YoY) and the FY2025 annual result came in at 88.66%, down 151.0% from the prior year.
- Gross Margin improved to 91.88% in Q1 2026, from 91.31% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 91.88% in Q1 2026 to a low of 85.34% in Q2 2025.
- A 5-year average of 88.98% and a median of 88.76% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin surged 397 bps — and 2025, when it sank 446 bps.
- Tracing URGN's Gross Margin over 5 years: stood at 87.49% in 2022, then grew by 3 bps to 90.28% in 2023, then slipped by 0 bps to 89.94% in 2024, then grew by 2 bps to 91.31% in 2025, then rose by 1 bps to 91.88% in 2026.
- The last three Gross Margin figures came in at 91.88% (Q1 2026), 91.31% (Q4 2025), and 88.07% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 90.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.93% |
| Mar 31, 2026 | 91.88% |
| Dec 31, 2025 | 91.31% |
| Sep 30, 2025 | 88.07% |
| Jun 30, 2025 | 85.34% |
| Mar 31, 2025 | 88.50% |
| Dec 31, 2024 | 89.94% |
| Sep 30, 2024 | 90.27% |
| Jun 30, 2024 | 89.80% |
| Mar 31, 2024 | 90.80% |
| Dec 31, 2023 | 90.28% |
| Sep 30, 2023 | 88.65% |
| Jun 30, 2023 | 88.44% |
| Mar 31, 2023 | 86.83% |
| Dec 31, 2022 | 87.49% |
| Sep 30, 2022 | 87.45% |
| Jun 30, 2022 | 88.88% |
| Mar 31, 2022 | 88.76% |
| Dec 31, 2021 | 90.18% |
| Sep 30, 2021 | 89.04% |